Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 900 shares, a growth of 28.6% from the October 31st total of 700 shares. Based on an average trading volume of 17,800 shares, the short-interest ratio is currently 0.1 days.

Immatics Trading Down 20.2 %

Shares of NASDAQ:IMTXW traded down $0.10 on Monday, hitting $0.40. 959,351 shares of the company were exchanged, compared to its average volume of 16,574. The stock’s 50 day moving average price is $1.23 and its 200 day moving average price is $2.29. Immatics has a 1-year low of $0.35 and a 1-year high of $4.14.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.